How to perform leukapheresis for procurement ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
URL permanente :
Titre :
How to perform leukapheresis for procurement of the staring material used for commercial car t-cell manufacturing: a consensus from experts convened by the sfgm-tc
Auteur(s) :
Carnoy, Sylvie [Auteur]
Beaumont, Jean-Louis [Auteur]
Kanouni, Tarik [Auteur]
Parquet, Nathalie [Auteur]
Beauvais, David [Auteur]
Hequet, Olivier [Auteur]
Kanold, Justina [Auteur]
Ballot, Caroline [Auteur]
Mialou, Valerie [Auteur]
Reppel, Loic [Auteur]
Damaj, Gandhi [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Chabannon, Christian [Auteur]
Beaumont, Jean-Louis [Auteur]
Kanouni, Tarik [Auteur]
Parquet, Nathalie [Auteur]
Beauvais, David [Auteur]
Hequet, Olivier [Auteur]
Kanold, Justina [Auteur]
Ballot, Caroline [Auteur]
Mialou, Valerie [Auteur]
Reppel, Loic [Auteur]
Damaj, Gandhi [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Chabannon, Christian [Auteur]
Titre de la revue :
Bulletin du cancer
Nom court de la revue :
Bull Cancer
Date de publication :
2021-02-17
ISSN :
1769-6917
Mot(s)-clé(s) :
B-cell acute lymphoblastic leukemia
CAR T-cells
Diffuse large B-cell lymphoma
Cytapheresis
CAR T-cells
Diffuse large B-cell lymphoma
Cytapheresis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present ...
Lire la suite >Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant cells. In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta™) is the treatment of relapsed/refractory DLBCL and mediastinal B-cell lymphoma. Both products are "living drugs" and genetically modified autologous T cells directed against CD19 which is an antigen expressed throughout B lymphoid differentiation and on many B malignancies. This collaborative work - part of a series of expert works on the topic - aims to provide practical advice to assist collection facilities that procure the starting material i.e. blood mononuclear cells for autologous CAR T-cell manufacturing.Lire moins >
Lire la suite >Chimeric antigen receptor (CAR) T-cells are a new class of cancer treatments manufactured through autologous or allogeneic T cells genetic engineering to induce CAR expression directed against a membrane antigen present at the surface of malignant cells. In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta™) is the treatment of relapsed/refractory DLBCL and mediastinal B-cell lymphoma. Both products are "living drugs" and genetically modified autologous T cells directed against CD19 which is an antigen expressed throughout B lymphoid differentiation and on many B malignancies. This collaborative work - part of a series of expert works on the topic - aims to provide practical advice to assist collection facilities that procure the starting material i.e. blood mononuclear cells for autologous CAR T-cell manufacturing.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:50:07Z